Gold+
- Enabling precision medicine with comprehensive genomic profiling
Speaker 1: Damon Hostin, Senior Director Market Access, Illumina
Speaker 2: Yeul Hong Kim, Korea University Anam Hospital
Session Introduction:
In 2017, South Korea was amongst the first countries to grant a selective reimbursement to NGS testing to inform the management of advanced cancer patients. In this session, we will review how NGS has been implemented in the clinical setting, the impact on patient management and the needs to ensure optimal access.
With NGS being now part of clinical routine in South Korea, we will then discuss the benefits of shifting over to the comprehensive genomic profiling approach. This discussion will cover the benefits for: the patients and oncologists (clinical utility), the pathologists as well as the payers (economic utility).
| Address | 14F Hi Investment & Securities Building 66 Yeoidaero, Yeoungdeungpo-gu, Seoul Korea (07325) | ||
|---|---|---|---|
| Telephone | 02-740-5300 | Fax | 02-786-8368 |
| Website | https://sapac.illumina.com/index-kr.html | customercare@illumina.com | |
Advancements in our understanding of genetics have the potential to change the practice of medicine and enable genomics-based healthcare. With streamlined workflows and advanced informatics, Illumina sequencing and array technologies and analysis services are allowing you to explore the genome more than ever before. Together, we can address healthcare in ways never before imagined. Visit Illumina Satellite Symposium and booth to find out how.
The TruSight Oncology 500 portfolio enables pan-cancer comprehensive genomic profiling (CGP) for solid tumors from either blood or tissue biopsy samples. There are three assays in the portfolio, TruSight Oncology 500 and TruSight Oncology 500 High-Throughput for FFPE samples, as well as TruSight Oncology 500 ctDNA for blood plasma samples. They are designed to analyze 523 cancer-relevant genes and identify relevant biomarkers in guidelines and clinical research, including the immuno-oncology markers TMB and MSI. [*For Research Use Only. Not for use in diagnostic procedures. M-KR-00033]
The NovaSeq 6000 System provides users with the throughput, speed, and flexibility to complete projects faster and more economically than ever before. Leveraging proven Illumina next-generation sequencing (NGS) technology, multiple flow cell types, two library loading workflows, and various read length combinations, the NovaSeq 6000 System enables effective throughput scaling to suit virtually any study needs. NovaSeq 6000 Reagent Kits v1.5 offer benefits including an improved Q30 score, support for UMIs, an extended shelf life of six months, and are compatible with TruSight Oncology 500 High-throughput and TruSight Oncology ctDNA. [*For Research Use Only. Not for use in diagnostic procedures. M-KR-00033]
